The role of carfilzomib in treatment of newly diagnosed multiple myeloma

Future Oncol. 2018 Dec;14(30):3123-3134. doi: 10.2217/fon-2018-0040. Epub 2018 Jul 30.

Abstract

Despite improvement of prognosis since approval of proteasome inhibitors and immunomodulatory drugs, myeloma remains largely incurable. The outcome of first-line treatment is known to be crucial for survival and, therefore, implementation of novel strategies remains one of the key aims of clinical myeloma research. Since approval of carfilzomib for relapsed and refractory multiple myeloma, a new therapeutic option with a favorable safety profile regarding neuropathy is available. Regarding its superior response rates and progression-free survival (PFS) when combined with other agents in heavily pretreated patients, the compound rapidly became a matter of great interest in search for first-line treatment. With an ORR up to 98% and promising PFS data, it might become an important partner in treatment of newly diagnosed myeloma.

Keywords: carfilzomib; first-line-treatment; induction; maintenance; multiple myeloma; newly diagnosed; proteasome inhibitor.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cardiovascular Diseases / chemically induced
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Oligopeptides / administration & dosage
  • Oligopeptides / adverse effects
  • Oligopeptides / pharmacokinetics
  • Oligopeptides / therapeutic use*
  • Proteasome Endopeptidase Complex / metabolism
  • Treatment Outcome

Substances

  • Oligopeptides
  • carfilzomib
  • Dexamethasone
  • Cyclophosphamide
  • Proteasome Endopeptidase Complex
  • ATP dependent 26S protease